Eli Lilly’s Retatrutide Shows Promise in Diabetes Trials, Fueling Next-Gen Obesity Drug Race

Eli Lilly’s experimental obesity drug retatrutide has taken a major step forward in the battle against Type 2 diabetes, delivering promising results in its first late-stage clinical trial. The therapy, which works by targeting three key hormones that regulate hunger and metabolism, slashed blood sugar levels by nearly 2% and helped patients shed an average of 16.8% of their body weight over 40 weeks—outperforming many existing treatments. With obesity and diabetes medications projected to generate over $100 billion in annual sales by 2030, retatrutide’s success positions Lilly as a frontrunner in a rapidly evolving market where demand for effective, next-generation therapies has never been higher.

• Retatrutide reduced hemoglobin A1c—a key blood sugar metric—by 1.7% to 2% in diabetes patients over 40 weeks, meeting the trial’s primary goal.
• Patients on the highest dose lost an average of 16.8% of their body weight (36.6 pounds), with even stronger results in those who completed the full regimen.
• The drug mimics three hormones (GLP-1, GIP, glucagon), offering a more potent appetite-suppressing effect than single- or double-hormone treatments like Zepbound or Wegovy.
• Lilly plans to file for regulatory approval soon, with seven additional phase 3 trials expected by year-end to further validate retatrutide’s safety and efficacy.

How Retatrutide Works: A Triple-Hormone Breakthrough in Obesity and Diabetes Treatment

Retatrutide belongs to a new class of medications often referred to as "triple agonists," designed to target multiple pathways in the body that control blood sugar and appetite. Unlike existing drugs that focus on one or two hormones—such as Novo Nordisk’s semaglutide (Wegovy), which targets only GLP-1, or Eli Lilly’s tirzepatide (Zepbound), which targets GLP-1 and GIP—retatrutide simultaneously engages GLP-1, GIP, and glucagon receptors. This triple-action approach mimics the body’s natural post-meal signaling, enhancing satiety while slowing gastric emptying and improving insulin sensitivity.

Why the Three-Hormone Strategy Matters

The scientific rationale behind retatrutide’s design stems from decades of research into gut-brain communication. GLP-1 (glucagon-like peptide-1) reduces appetite and delays stomach emptying, while GIP (glucose-dependent insulinotropic polypeptide) enhances insulin secretion in response to meals. Glucagon, typically associated with raising blood sugar, is repurposed here to amplify weight loss by increasing energy expenditure. By combining these effects, retatrutide aims to address two critical challenges in metabolic disease: hyperglycemia (high blood sugar) and adiposity (excess body fat). Clinical trials suggest this approach delivers superior outcomes compared to single-hormone therapies, though direct head-to-head comparisons are still lacking.

Ken Custer, president of Lilly Cardiometabolic Health, emphasized the drug’s potential in an interview with CNBC, stating, "Patients with Type 2 diabetes historically struggle to lose weight, so Lilly is very excited to see that the drug led to both a competitive drop in blood sugar levels and significant weight loss." He added that the drug’s safety profile—with discontinuation rates due to side effects as low as 5%—further bolsters its promise as a viable treatment option.

Trial Results: Blood Sugar Control and Weight Loss Exceed Expectations

The phase 3 trial, which enrolled Type 2 diabetes patients with baseline hemoglobin A1c levels between 7% and 9.5%—a range indicating poorly controlled diabetes—showed retatrutide’s ability to deliver robust metabolic benefits. Across different doses, the drug reduced A1c by an average of 1.7% to 2% at the 40-week mark, a reduction that aligns with the most effective diabetes medications currently on the market. Weight loss results were equally striking: patients receiving the highest dose lost an average of 16.8% of their body weight (36.6 pounds), while those who discontinued treatment still averaged a 15.3% reduction. For context, Zepbound, Lilly’s blockbuster obesity drug, achieved a 13.1% weight loss in its SURPASS-2 trial and 11% in SURPASS-1 at the same 40-week interval.

Side Effects Mirror Class Norms, but Discontinuation Rates Remain Low

Like all GLP-1-based therapies, retatrutide’s most common side effects were gastrointestinal, including nausea (26.5% of patients on the highest dose), diarrhea (22.8%), and vomiting (17.6%). These symptoms, while manageable for most, contributed to the discontinuation of treatment for a small subset of participants. However, the overall rate of discontinuation due to adverse events hovered around 5%, a figure Custer called "relatively low" compared to similar drugs. Less common side effects included dysesthesia—a sensation of abnormal touch or pain—which affected a minority of patients but did not significantly impact the trial’s safety outcomes.

The Obesity-Diabetes Nexus: Why Lilly’s Bet on Retatrutide Could Reshape Treatment Algorithms

The convergence of obesity and Type 2 diabetes—conditions that often exacerbate one another—has created a critical unmet need in modern medicine. Approximately 40% of adults in the U.S. live with obesity, and nearly 1 in 10 Americans has diabetes, with Type 2 accounting for 90-95% of cases. Traditional diabetes medications, such as metformin, focus primarily on blood sugar control but do little to address weight gain, a common side effect of insulin and sulfonylureas. In contrast, retatrutide’s dual benefits—improving glycemic control while promoting weight loss—could lead to its adoption as a first-line therapy in patients with both conditions.

Personalized Medicine: Tailoring Treatments to Patient Needs

Custer highlighted the importance of individualized care in metabolic disease management, noting that not all patients will respond equally to the same treatment. "Choosing which drug to take will depend on individualized tailoring of solutions and patients," he explained. "Particularly earlier in their diabetes treatment, patients who want to regulate their blood sugar could benefit from either Zepbound or retatrutide. But if they are looking to lose more weight, the latter might be a better option." This nuanced approach reflects a broader shift in healthcare toward precision medicine, where therapies are selected based on genetic, metabolic, and lifestyle factors rather than a one-size-fits-all model.

The Competitive Landscape: Novo Nordisk Fights to Keep Up, and Others Are Racing to Enter

Eli Lilly’s dominance in the obesity-drug market has intensified competition, with Novo Nordisk—maker of Wegovy and Ozempic—scrambling to close the gap. In March 2025, Novo acquired exclusive rights to a preclinical obesity drug from China’s United Laboratories International for up to $2 billion, signaling its intent to develop a triple-hormone agonist of its own. While retatrutide is already in late-stage trials, Novo’s experimental drug is years away from potential approval, giving Lilly a significant head start. Other players, including Pfizer and Amgen, are also investing heavily in metabolic disease research, but none have yet matched the clinical progress of retatrutide or Zepbound.

Regulatory Pathway: What’s Next for Retatrutide?

Despite the promising trial results, Eli Lilly has not yet submitted retatrutide for regulatory approval to the FDA or other global agencies. The company plans to report findings from seven additional phase 3 trials by the end of 2025, which will include data on retatrutide’s use in non-diabetic obesity patients—a critical population given the drug’s weight-loss potential. If these trials replicate the current results, Lilly is expected to file for approval in both diabetes and obesity indications, potentially positioning retatrutide as a blockbuster drug rivaling Zepbound and Wegovy. Analysts at firms like Leerink Partners have projected peak annual sales for retatrutide to exceed $10 billion, underscoring the high stakes in this market.

Market Dynamics: Why Obesity Drugs Are Becoming a $100 Billion Opportunity

The global obesity drug market has exploded in recent years, driven by the growing prevalence of metabolic diseases and the introduction of GLP-1-based therapies. In 2023, the market was valued at approximately $30 billion, but it is projected to surpass $100 billion by 2030, according to industry estimates from firms like Morgan Stanley. This growth is fueled by several factors: increasing obesity rates (now affecting over 42% of U.S. adults), rising healthcare costs associated with diabetes complications, and a cultural shift toward accepting medical interventions for weight management. Additionally, the success of drugs like Ozempic and Zepbound has validated the viability of obesity pharmacotherapy, opening the door for next-generation treatments like retatrutide.

The Role of Insurance and Accessibility in the Obesity Drug Boom

While the clinical efficacy of these drugs is well-documented, access remains a major barrier for many patients. The list price for Zepbound, for example, is approximately $1,000 per month without insurance, and Wegovy’s price is slightly lower but still prohibitive for uninsured individuals. Insurance coverage for obesity medications varies widely, with many plans requiring prior authorization or excluding them from formularies altogether. Eli Lilly has pledged to expand patient assistance programs to improve affordability, but the high cost of production—retatrutide’s manufacturing process is complex due to its triple-hormone mechanism—could keep prices elevated. Policymakers and insurers are now grappling with how to balance innovation with accessibility in this rapidly evolving landscape.

Historical Context: How Retatrutide Fits Into the Evolution of Obesity and Diabetes Drugs

The development of obesity drugs has undergone a dramatic transformation over the past two decades. Early treatments, such as fenfluramine-phentermine (fen-phen) in the 1990s, were withdrawn due to safety concerns, including heart valve damage. The FDA’s approval of orlistat (Xenical) in 1999 marked a turning point, but its modest efficacy and gastrointestinal side effects limited its use. The real revolution began in 2014 with the approval of liraglutide (Saxenda), the first GLP-1-based obesity drug, which demonstrated that targeting gut hormones could drive meaningful weight loss. This was followed by semaglutide (Wegovy) in 2021, which achieved weight loss of up to 15% in clinical trials—results that led to Wegovy’s designation as a "breakthrough" therapy. Retatrutide represents the next evolutionary leap, combining the benefits of GLP-1 and GIP with the metabolic-boosting effects of glucagon, potentially offering a more comprehensive solution for patients.

The Future of Metabolic Disease Treatment: What’s on the Horizon?

Beyond retatrutide, the pipeline for obesity and diabetes drugs is more crowded than ever. Companies are exploring oral formulations, combination therapies, and even gene-editing approaches to address metabolic disease. For example, Lilly’s orforglipron, an oral GLP-1 receptor agonist, is in late-stage trials and could provide a more convenient alternative to injectable drugs. Meanwhile, Novo Nordisk is testing cagrilintide, a long-acting amylin analog, in combination with semaglutide to enhance weight loss. The FDA’s recent guidance on obesity drug approvals—including a focus on cardiovascular outcomes—also suggests that future therapies will need to demonstrate broader health benefits beyond just weight reduction. As the science advances, the line between obesity and diabetes treatments may blur further, with drugs like retatrutide serving as the vanguard of this new era.

Regional Manufacturing and Supply Chain Considerations

Eli Lilly’s strategic decision to invest $6.5 billion in a new manufacturing facility in Texas underscores the company’s long-term commitment to scaling production of retatrutide and other high-demand drugs. The facility, slated for completion in the late 2020s, will house advanced bioreactors and purification systems capable of producing millions of doses annually. This move aligns with broader trends in the pharmaceutical industry, where companies are seeking to reduce reliance on overseas supply chains—particularly in light of geopolitical tensions and post-pandemic disruptions. By localizing production, Lilly aims to ensure a stable supply of retatrutide to meet global demand while mitigating risks associated with global logistics and trade policies.